Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EspacECU: Personalized Eculizumab Spacing in aHUS
NCT04859608Phase 3Completed
- Sponsor
- University Hospital Tours
- Start
- Oct 2021
- Primary completion
- Jun 2022
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of eculizumab in atypical hemolytic uremic syndrome (aHUS), sponsored by University Hospital Tours. Primary endpoint: Incremental Cost-Utility Ratio at 18 months. Started Oct 2021; status: completed.
02
Drugs
eculizumab
03
Conditions
atypical hemolytic uremic syndrome (aHUS)
Beyond the preview
Go deeper on NCT04859608.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04859608.